Deerfield Management Company, L.P. (Series C) Merus N.V. Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.04 Billion
- Q4 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Merus N.V. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 2,972,787 shares of MRUS stock, worth $126 Million. This represents 3.1% of its overall portfolio holdings.
Number of Shares
2,972,787
Previous 3,408,539
12.78%
Holding current value
$126 Million
Previous $170 Million
26.59%
% of portfolio
3.1%
Previous 3.17%
Shares
11 transactions
Others Institutions Holding MRUS
# of Institutions
201Shares Held
60.7MCall Options Held
111KPut Options Held
85.7K-
Rtw Investments, LP New York, NY4.17MShares$176 Million2.86% of portfolio
-
Commodore Capital LP New York, NY3.87MShares$164 Million16.32% of portfolio
-
Wellington Management Group LLP Boston, MA3.5MShares$148 Million0.03% of portfolio
-
Samlyn Capital, LLC New York, NY2.67MShares$113 Million1.81% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.13MShares$89.8 Million1.3% of portfolio
About Merus N.V.
- Ticker MRUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,878,200
- Market Cap $1.94B
- Description
- Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...